🇺🇸 Why does so much pharmaceutical innovation come from small biotech companies? And how do different parts of America's medicine ecosystem work together to turn scientific discoveries into medicines for patients?

In this episode of How America Makes Medicine, John Stanford sits down with Dr. Jeremy Levin, a longtime pharmaceutical and biotechnology leader, to explore the interconnected ecosystem behind American drug innovation and the complementary roles of small biotech companies and larger pharmaceutical manufacturers.

Levin's career includes leadership roles at Novartis, Bristol-Myers Squibb, Teva Pharmaceuticals, and Ovid Therapeutics. He also discusses the "String of Pearls" strategy, a targeted approach to acquisitions and partnerships designed to strengthen pharmaceutical pipelines and advance promising innovations.

The conversation examines why small biotech companies are an important source of innovation, while larger pharmaceutical manufacturers contribute scientific expertise, capital, manufacturing capabilities, regulatory experience and global infrastructure. Together, these different strengths help move discoveries from research and development toward patients.

The episode also explores drug pricing policy, Most Favored Nation pricing, the Inflation Reduction Act, venture capital, pharmaceutical regulation and biotech investment, including how policy uncertainty can affect the development of future medicines.

Levin also discusses China's growing biotechnology capabilities and America's global innovation advantage, arguing that the United States must continue strengthening its research infrastructure, technical expertise and investment environment to remain a leader in biotechnology and drug development.

We explore:
🔹 Small biotech and pharmaceutical innovation
🔹 Small biotech and larger pharmaceutical manufacturers
🔹 Jeremy Levin and the "String of Pearls" strategy
🔹 Bristol-Myers Squibb and biotech acquisitions
🔹 Drug discovery and development
🔹 Venture capital and biotech investment
🔹 Drug pricing and pharmaceutical policy
🔹 Most Favored Nation pricing and the Inflation Reduction Act
🔹 NIH, FDA and America's research ecosystem
🔹China's growing role in biotechnology
🔹 America's global biotechnology advantage
🔹 Innovation, investment and patient access

How America Makes Medicine is a seven-part series exploring the people, science, institutions and business decisions behind 250 years of American pharmaceutical innovation.

From research universities and biotechnology startups to pharmaceutical manufacturers, investors, regulators and patients, the series examines how America's medicine ecosystem was built and what it will take to keep innovating.

Technical note: Near the end of the episode, Dr. Levin loses his internet connection and continues the conversation by phone. His video is temporarily replaced with a still image while the conversation continues.

Watch the full episode and let us know your thoughts below ⬇️
What role should small biotech companies play in America's future drug-development strategy?
Can the United States maintain its biotechnology advantage as global competition increases?
Drop your thoughts in the comments below 👇

👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part documentary series celebrating 250 years of American pharmaceutical innovation.

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Timestamps
00:00 Jeremy Levin and America's Biotech Innovation Engine
00:38 Jeremy Levin's Career in Pharmaceutical Innovation
03:04 The "String of Pearls" Strategy
05:37 The Birth of America's Biotechnology Industry
07:19 Why Patients Drive Drug Development
11:56 How Biotech Acquisitions Strengthen Drug Pipelines
16:20 Small Biotech and Larger Pharmaceutical Manufacturers
20:20 Why Small Biotech Drives Drug Innovation
21:43 Drug Pricing, Policy and Biotech Investment
28:10 How Policy Uncertainty Affects Drug Development
38:35 Biotech in the Balance: America's Innovation Advantage
40:57 NIH, FDA and America's Research Ecosystem
42:20 China and the Global Biotechnology Race
46:58 Protectionism and the Future of Innovation
49:09 How America Can Compete Through Innovation
50:44 The Football Analogy: Who Will Win?

DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.  

#HowAmericaMakesMedicine #MakingMedicine #biotech #drugdevelopment #pharmaceuticalinnovation #lifesciences #medicalinnovation #biotechnology